Merck has not shied away from splashy takeovers in the past. In 2015, the company agreed to buy U.S. lab equipment supplier ...

Most companies don't survive for decades, much less pay regular dividends for that long. Healthcare leaders Merck (NYSE: MRK) ...

On Monday, Germany-based Merck KGaA (OTC ... Additionally, SpringWorks’ products have the potential to help counter revenue losses from expiring drug patents and increased competition.

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks ... estimates could grow to become a $800 million-plus product. FDA approval means that Gomekly becomes only the ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

SpringWorks expects to have two products on the market by 2025. Investors responded positively to the news. SpringWorks' shares jumped 34% on Monday and reached their highest level since April 2022.

drug, which also goes by the name sotatercept, was originally picked up via Merck’s $11.5 billion acquisition of Acceleron back in 2021. The U.K.’s Medicines and Healthcare products Regulatory ...

The rise of misinformation online has helped fringe health ideas go mainstream and eased RFK Jr.'s path to confirmation as ...

Merck is taking an exclusive commercial license to the drug – called pimicotinib (ABSK021 ... designations by China National Medical Products Administration (NMPA) and the FDA in the ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...